Pranax

At Visolis, we use synthetic biology to manufacture high performance materials. Our systems approach integrates innovations in synthetic biology, chemical catalysis and process scale-up to enable new bio-based manufacturing platforms. Our unique bio-based process enables us to achieve true carbon-negative chemical synthesis. Visolis is located in Hayward, CA and Geleen, Netherlands, with close collaborations with Lawrence Berkeley National Lab, Pacific Northwest National Lab and University of California, Berkeley. We have received funding from the Bill and Melinda Gates Foundation, US Department of Energy, the National Science Foundation and the U.S. Department of Agriculture.

Elysium Therapeutics is a health care company that focuses on biotechnology, fitness, medical, and robotics. It was founded in 2013 and headquartered in Danville, California.

Cellares develops the Cell Shuttle, to overcome the challenges associated with manufacturing so these life-saving therapies are affordable and widely available to patients who can benefit. The clinical impact of cell therapy in treating cancer has been proven, but this therapeutic approach has several limitations, especially in manufacturing, leaving extremely sick patients waiting for treatment and desperate for hope. Since cell therapy is currently produced for a single patient at a time, it is expensive to manufacture, requiring significant time and resources and is difficult to scale. Preclinical and clinical scientists, as well as commercial cell therapy manufacturers also lack the options to fully automate their manufacturing process quickly, safely, cost-effectively, and at the scale they need. The Cell Shuttle is an automated and closed end-to-end manufacturing solution that is flexible and scalable, enabling customers to run exact processes specified for their cell therapy. Compared with the current manual manufacturing processes for cell therapy, the Cell Shuttle’s next-generation automated manufacturing solution has 10 times the scalability (meaning 10 times more patient doses can be produced simultaneously), enables a three-fold reduction in process failure rates, and will reduce the per-patient manufacturing cost by up to 70 percent for most processes.

Antheia focuses on creating biosynthetic key starting materials (KSMs) and active pharmaceutical ingredients (APIs) for important medications through synthetic biology. By manipulating yeast to recreate intricate biosynthetic pathways, the company transforms basic sugars into pharmaceutical substances using fermentation. This method is designed to lessen the need for traditional farming sources and chemical production, providing a more dependable supply chain. Antheia's range of products includes compounds for medical fields like neurology, oncology, and gastroenterology. The company assists pharmaceutical collaborators from initial development to regulatory approval to promote the use of biomanufactured ingredients.

Imbed Biosciences, Inc is a privately owned medical device company that is working on developing innovative technologies for incorporating bioactive substances into wound dressings and surgical implants. Through its unique biomaterials platforms, Imbed is transforming wound dressings to prevent infections and speed up wound healing. Ultimately, this could help reduce the overall cost of managing surgical and chronic wounds, which represents a $3 billion market opportunity in the U.S. and Europe. Imbed was created as a spin-off from the University of Wisconsin-Madison, building on four years of research conducted by a team of engineers, veterinary scientists, and medical surgeons. Together, the founders have more than 25 years of experience in clinical wound management.

Barnwell Bio analyzes waste streams for insights into animal health and farm management.

Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability.

DAXOR Corporation is a groundbreaking medical technology company that has created the BVA-100 Blood Volume Analyzer, the first FDA-approved device that can quickly and accurately measure a patient's blood volume. The company believes that this innovative instrument has the potential to revolutionize treatment in various medical and surgical settings. DAXOR aims to collaborate with hospitals and clinics to make this transformation a reality. The BVA-100 is a semi-automated device that requires a single use diagnostic kit, and it is the only FDA-approved instrument for direct blood volume measurement.

PAQ Therapeutics is a biotechnology company that is at the forefront of developing a different method to improve health and treat illness by harnessing the power of autophagy, the body's highly adaptable process for breaking down cells naturally.

Kaida BioPharma develops therapies for treatment-resistant gynecological cancers, focusing on ovarian cancer and hormone-driven diseases.

Ocugen is a biopharmaceutical company in the clinical stage that is dedicated to researching, developing, and selling gene therapies to treat eye diseases that can cause blindness. They are also working on developing a COVID-19 vaccine to help save lives. Their biologic product candidate is aimed at providing improved treatment options for patients with diseases like wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy, using a cutting-edge modifier gene therapy platform.

Corvus Pharmaceuticals is a biopharmaceutical company in the clinical stage that is dedicated to creating groundbreaking treatments for cancer by targeting the immune system. We have a team of skilled scientists and strong financial backing, which puts us in a prime position in the evolving field of immuno-oncology.